RxDoctor Payments Data

George Leber, MD

Cardiovascular Disease · Englewood, NJNPI 1275636060

Payments from drug & device makers

$5,253in general payments, 2019–2025

Across 412 payments — averaging $12.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$982
  • Pfizer$404
  • Johnson & Johnson$361
  • Merck$327
  • E.r. Squibb & Sons, L.L.C.$322
  • Amgen$291
  • plus $3K from 33 others

What the payments were for

  • Food & beverage$5,16998%
  • Education$842%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,253 in reported general payments places this provider in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.

See all cardiovascular disease providers in New Jersey

Medicare billing

Part B allowed, 2024
$316,566
Medicare patients
989
Services billed
4,899

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis24$823,205
EliquisApixaban441$487,397
JardianceEmpagliflozin138$153,831
XareltoRivaroxaban129$136,277
Repatha SureclickEvolocumab59$66,598
OzempicSemaglutide61$62,457
EntrestoSacubitril/Valsartan57$58,549
MounjaroTirzepatide52$58,150
FarxigaDapagliflozin Propanediol46$47,157
BrilintaTicagrelor34$20,911
WegovySemaglutide11$17,633
Bisoprolol Fumarate286$9,533
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,286
Rosuvastatin Calcium384$7,631
Atorvastatin Calcium538$6,740

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$404$1,310,602465 claims
Boehringer IngelheimJardiance$161$153,831138 claims
Johnson & JohnsonXarelto$361$136,277129 claims
Novo NordiskOzempic, Wegovy$126$80,09072 claims
AstraZenecaFarxiga, Brilinta, Crestor$239$73,15291 claims
NovartisEntresto$982$58,54957 claims
Lilly USA, LLCMounjaro$52$58,15052 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,006 cardiovascular disease providers in New Jersey.

Other cardiovascular disease in Englewood

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →